T2 Biosystems Announces Webinar and White Paper Highlighting T2Candida Panel Clinical Data and Best Practices

LEXINGTON, Mass., April 05, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the availability of a new webinar and white paper highlighting the T2Candida Panel clinical data and best practices from real world use within Medical Intensive Care Units (MICU). “The T2Candida Panel is a valuable tool for the management of critically ill patients,” stated Dr. Neil Clancy, Chief of Infectious Diseases for the VA Pittsburgh Healthcare System, and Tenured Professor of Medicine, Associate Chief of Infectious Diseases and Director of the XDR Pathogen Lab…